Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer.

Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer.
复制标题

DOI:
--
复制
发表时间:
1995-02
期刊:
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子:
--
通讯作者:
M. D. Renzo;M. Olivero;A. Giacomini;H. Porte;E. Chastre;L. Mirossay;B. Nordlinger;S. Bretti-S.-Bret
M. D. Renzo;M. Olivero;A. Giacomini;H. Porte;E. Chastre;L. Mirossay;B. Nordlinger;S. Bretti-S.-Bret
中科院分区:
其他
文献类型:
--
作者:
M. D. Renzo;M. Olivero;A. Giacomini;H. Porte;E. Chastre;L. Mirossay;B. Nordlinger;S. Bretti-S.-Bret

文献摘要

被引文献

相似文献

c-met癌基因编码肝细胞生长因子/分散因子的受体,这是一种有效的上皮细胞有丝分裂原,也可促进细胞运动性和侵袭性。我们研究了c-met基因表达在结直肠肿瘤进展过程中的变化。检查了16个腺瘤,123个原始癌和25个肝转移瘤。在一些情况下,可以比较同一患者的正常结肠粘膜样本与原发性肿瘤样本和原发性癌样本与同步转移样本。c-met基因的表达在任何进展阶段的约50%的肿瘤和70%的肝转移瘤中从5倍增加到50倍。过度表达与c-met基因扩增相关,仅10%的癌,但在9个转移检查8。这些数据表明,c-met癌基因的过度表达有助于肿瘤性结直肠细胞在肿瘤进展的任何阶段的选择性生长优势。此外,扩增似乎为获得转移潜能提供了进一步的选择性优势。
The c-met oncogene encodes the receptor for hepatocyte growth factor/scatter factor, a potent mitogen for epithelial cells that also promotes cell motility and invasiveness. We have studied the changes of c-met gene expression that occur during the progression of colorectal tumors. Sixteen adenomas, 123 primitive carcinomas, and 25 liver metastases were examined. In several instances it was possible to compare same-patient samples of normal colon mucosa against primary tumor and primary carcinoma against synchronous metastasis. The expression of the c-met gene was increased from 5- to 50-fold in about 50% of tumors, at any stage of progression, and in 70% of liver metastases. Overexpression was associated with amplification of the c-met gene in only 10% of carcinomas, but in 8 of 9 metastases examined. These data suggest that overexpression of the c-met oncogene contributes a selective growth advantage to neoplastic colorectal cells at any stage of tumor progression. Moreover, amplification appears to give a further selective advantage for the acquisition of metastatic potential.